Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Revenue (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Revenue for 9 consecutive years, with $192000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Revenue fell 66.37% year-over-year to $192000.0, compared with a TTM value of $192000.0 through Sep 2025, down 76.59%, and an annual FY2024 reading of $441000.0, down 77.08% over the prior year.
  • Revenue was $192000.0 for Q4 2024 at Avalo Therapeutics, down from $249000.0 in the prior quarter.
  • Across five years, Revenue topped out at $14.9 million in Q3 2022 and bottomed at $192000.0 in Q4 2024.
  • Average Revenue over 5 years is $1.8 million, with a median of $964500.0 recorded in 2022.
  • The sharpest move saw Revenue soared 1007.33% in 2022, then crashed 98.42% in 2023.
  • Year by year, Revenue stood at $1.5 million in 2020, then tumbled by 85.37% to $219000.0 in 2021, then skyrocketed by 309.13% to $896000.0 in 2022, then crashed by 36.27% to $571000.0 in 2023, then crashed by 66.37% to $192000.0 in 2024.
  • Business Quant data shows Revenue for AVTX at $192000.0 in Q4 2024, $249000.0 in Q3 2024, and $571000.0 in Q4 2023.